Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

BACKGROUND: We investigated the use of the gonadotropin-releasing hormone (GnRH) antagonist degarelix in everyday clinical practice using registry data from uro-oncology practices in Germany. METHODS: Data were analysed retrospectively from the IQUO (Association for uro-oncological quality assurance...

Descripción completa

Detalles Bibliográficos
Autores principales: Geiges, Götz, Harms, Thomas, Rodemer, Gerald, Eckert, Ralf, König, Frank, Eichenauer, Rolf, Schroder, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681133/
https://www.ncbi.nlm.nih.gov/pubmed/26674089
http://dx.doi.org/10.1186/s12894-015-0116-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681133/
https://www.ncbi.nlm.nih.gov/pubmed/26674089
http://dx.doi.org/10.1186/s12894-015-0116-4

Ejemplares similares